Today we have Juliette Audet with us. Juliette is a Partner at Forbion a multi-stage venture fund in Amsterdam and Munich backing biotech companies in Europe and North America to impact the future of medicine.Forbion is investing out of 2 separate funds: Forbion Ventures Fund VI and Forbion Growth Opportunities Fund II, of €750M and €600M respectively, with a total of 3b EUR AUM and an established portfolio of 44 companies, with notable investment including NewAmsterdam Pharma, Gyroscope and Inflazome. At Forbion, Juliette focuses on the Venture strategy, investing in biotech companies from pre-clinical stage to Phase 1b and led the investments in NewAmsterdam Pharma, Mestag and Dualyx amongst others.Jump to the parts that matter most to you ?00:02:10 - Transitioning from Consulting to Pharma and Biotech00:03:44 - Discipline and Resilience in Career00:05:18 - Recognizing the Moment to Fold00:07:17 - The Importance of Science and Interaction in Investments00:08:50 - The Importance of Board Dynamics00:10:25 - Board Composition and Power Dynamics00:12:07 - Creating Consensus on the Board00:13:37 - The Importance of Governance in Building an Effective Board00:14:53 - Governance and relationship building with board members00:16:35 - The Benefits of Virtual Board Meetings00:18:21 - The Importance of Providing Value00:20:30 - The Value of External Perspective in VC00:22:21 - The Unique Nature of Biotech Companies00:23:57 - Pharma's Need for External Acquisitions00:25:47 - The Inflection Point in BioTech00:27:16 - Slump in M&A Activity in Pharma-Biotech & the dawning opportunity00:28:34 - The Development Process from Preclinical to Phase 300:29:58 - The Dynamic between CVCs and Institutional VCs in BioTech00:33:14 - The Predictability of Biotech VC vs Traditional Venture00:34:54 - Shoutout to Julie Grant from Canaan00:36:33 - Balance and Fulfillment in VC00:38:21 - Getting to know your LPs